Advanced Non-Small Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : June 7, 2026
- Updated On : September 4, 2026
- Pages : 154
Advanced Non-Small Cell Lung Cancer Market Outlook and Forecast
Thelansis’s “Advanced Non-Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Non-Small Cell Lung Cancer Overview
Advanced non-small cell lung cancer is a biologically heterogeneous malignancy requiring treatment selection based on histology, actionable genomic alterations, PD-L1 expression, and prior therapy. Current management has evolved from chemotherapy toward molecularly targeted therapies for oncogene-driven tumors and immunotherapy-based regimens for cancers without actionable drivers, supported by broad molecular testing across NSCLC. Despite major improvements in outcomes, primary and acquired resistance, clonal evolution, CNS progression, and tumor-immune escape continue to limit durable disease control. The therapeutic landscape is therefore expanding beyond established targeted and immune therapies into next-generation modalities, including antibody-drug conjugates, bispecific immune-engaging antibodies, and agents designed to address specific mechanisms of resistance. ADCs are particularly active, with approved examples such as telisotuzumab vedotin and datopotamab deruxtecan in defined NSCLC populations and additional targets advancing through clinical development. A notable September 2026 development is the investigational CTLA-4-targeting antibody gotistobart, which reported median overall survival of 18.5 months versus 10.0 months with chemotherapy in the non-pivotal stage 1 of a Phase 3 trial in previously treated squamous NSCLC after immunotherapy and chemotherapy. For stakeholders, advanced NSCLC remains a high-value precision-oncology frontier where the next advances will depend on overcoming resistance while extending both systemic and intracranial disease control across increasingly defined patient subsets.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Advanced Non-Small Cell Lung Cancer Market Outlook and Forecast
Thelansis’s “Advanced Non-Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced Non-Small Cell Lung Cancer Overview
Advanced non-small cell lung cancer is a biologically heterogeneous malignancy requiring treatment selection based on histology, actionable genomic alterations, PD-L1 expression, and prior therapy. Current management has evolved from chemotherapy toward molecularly targeted therapies for oncogene-driven tumors and immunotherapy-based regimens for cancers without actionable drivers, supported by broad molecular testing across NSCLC. Despite major improvements in outcomes, primary and acquired resistance, clonal evolution, CNS progression, and tumor-immune escape continue to limit durable disease control. The therapeutic landscape is therefore expanding beyond established targeted and immune therapies into next-generation modalities, including antibody-drug conjugates, bispecific immune-engaging antibodies, and agents designed to address specific mechanisms of resistance. ADCs are particularly active, with approved examples such as telisotuzumab vedotin and datopotamab deruxtecan in defined NSCLC populations and additional targets advancing through clinical development. A notable September 2026 development is the investigational CTLA-4-targeting antibody gotistobart, which reported median overall survival of 18.5 months versus 10.0 months with chemotherapy in the non-pivotal stage 1 of a Phase 3 trial in previously treated squamous NSCLC after immunotherapy and chemotherapy. For stakeholders, advanced NSCLC remains a high-value precision-oncology frontier where the next advances will depend on overcoming resistance while extending both systemic and intracranial disease control across increasingly defined patient subsets.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)